GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (XTER:1SXP) » Definitions » Cash, Cash Equivalents, Marketable Securities

Schott Pharma AG KGaA (XTER:1SXP) Cash, Cash Equivalents, Marketable Securities : €23.7 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Schott Pharma AG KGaA Cash, Cash Equivalents, Marketable Securities?

Schott Pharma AG KGaA's quarterly cash, cash equivalents, marketable securities declined from Jun. 2024 (€29.52 Mil) to Sep. 2024 (€26.43 Mil) but then stayed the same from Sep. 2024 (€26.43 Mil) to Dec. 2024 (€23.73 Mil).

Schott Pharma AG KGaA's annual cash, cash equivalents, marketable securities declined from Sep. 2022 (€30.28 Mil) to Sep. 2023 (€25.89 Mil) but then increased from Sep. 2023 (€25.89 Mil) to Sep. 2024 (€26.43 Mil).


Schott Pharma AG KGaA Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Schott Pharma AG KGaA's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA Cash, Cash Equivalents, Marketable Securities Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24
Cash, Cash Equivalents, Marketable Securities
18.61 27.86 30.28 25.89 26.43

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.96 26.41 29.52 26.43 23.73

Schott Pharma AG KGaA Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Schott Pharma AG KGaA  (XTER:1SXP) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Schott Pharma AG KGaA Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Schott Pharma AG KGaA Business Description

Traded in Other Exchanges
Address
Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.
Executives
Dr. Jens Schulte Supervisory Board
Andreas Reisse Board of Directors
Ann-kristin Erkens Supervisory Board
Dr. Almuth Steinkühler Board of Directors
Dr. Wolfgang Wienand Supervisory Board
Peter Goldschmidt Supervisory Board

Schott Pharma AG KGaA Headlines

No Headlines